Vaccines with biomolecular adjuvants

Patent metadata

Field	Value
Publication number	US-10226528-B2
Application number	US-201414774428-A
Country	US
Kind code	B2
Filing date	Mar 14, 2014
Priority date	Mar 15, 2013
Publication date	Mar 12, 2019
Grant date	Mar 12, 2019

Abstract

Disclosed herein is a vaccine comprising an antigen and one or more bimolecular adjuvant. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.

First claim

What is claimed is:

1. A vaccine comprising a nucleotide sequence encoding an antigen and a nucleotide sequence encoding Rel-A, wherein the nucleotide sequence encoding Rel-A comprises SEQ ID NO: 1.

2. The vaccine of claim 1 , wherein the vaccine comprises a first nucleic acid molecule encoding the antigen and a second nucleic acid molecule encoding RelA.

3. The vaccine of claim 2 , wherein the second nucleic acid molecule comprises an expression vector.

4. The vaccine of claim 1 , wherein the antigen is selected from a group consisting of a human papilloma virus (HPV) antigen, an HIV antigen, an influenza antigen, a Plasmodium falciparum antigen and a fragment thereof.

5. The vaccine of claim 4 , wherein the HIV antigen is selected from the group consisting of Env A, Env B, Env C, Env D, B Nef-Rev, Gag and any combination thereof.

6. The vaccine of claim 4 , wherein the influenza antigen is selected from the group consisting of H1 HA, H2 HA, H3 HA, H5 HA, BHA antigen and any combination thereof.

7. The vaccine of claim 4 , wherein the Plasmodium falciparum antigen includes a circumsporozoite (CS) antigen.

8. The vaccine of claim 4 , wherein the HPV antigen is selected from the group consisting of HPV16 E6 antigen, an HPV16 E7 antigen, and a combination thereof.

9. The vaccine of claim 1 , further comprising a pharmaceutically acceptable excipient.

10. A method for increasing an immune response in a subject, the method comprising administering the vaccine of claim 1 to the subject in need thereof.

11. The method of claim 10 , wherein administering the vaccine includes at least one of intramuscular administration and intradermal administration.

12. The method of claim 10 , wherein administering the vaccine includes electroporation.

13. The method of claim 10 , wherein the immune response in the subject is increased by about 50% to about 150%.

14. The method of claim 13 , wherein the immune response in the subject is increased by about 90% to about 130%.

15. The method of claim 14 , wherein the immune response in the subject is increased by about 105%.

16. The method of claim 3 , wherein the immune response in the subject is increased by at least about 2.5-fold.

17. The method of claim 3 , wherein the immune response in the subject is increased by at least about 1.5 fold.

18. A nucleic acid molecule comprising nucleotide sequence SEQ ID NO: 1.

19. The nucleic acid molecule of claim 18 , wherein the nucleic acid molecule is one or more plasmids.

Assignees

• Weiner David B
• Muthumani Karuppiah
• Univ Pennsylvania

Inventors

• Weiner David B
• Muthumani Karuppiah

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P33/06

  Antimalarials · CPC title

• A61P31/20

  for DNA viruses · CPC title

• A61P31/18

  for HIV · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title